Call to Action: CMS Beta Amyloid Coverage Decision

July 25, 2013

On July 3, the Centers for Medicare and Medicaid Services (CMS) released a proposed decision on coverage for beta amyloid (Aβ) imaging.  In the decision, CMS stated there is insufficient evidence that the scan will improve health outcomes for patients with dementia or other neurodegenerative diseases.  SNMMI disagrees with the proposed decision and is encouraging its members to contact CMS and make their voices heard.  SNMMI requests members also reach out to referring physicians to encourage them to weigh in as well.

As you know, SNMMI joined with the Alzheimer’s Association earlier this year and developed appropriate use criteria (AUC) recommending when it is appropriate for a patient to receive the test.We believe CMS should immediately cover Aβ imaging following the clinical scenarios outlined in the AUC.

SNMMI will soon be submitting its comments to CMS.  Attached are bullet points highlighting SNMMI’s position.  Feel free to use these bullets as a guide for your own letter.

CMS needs to hear how Aβ imaging improves health outcomes for your patients.  Contact CMS before the August 2 deadline.  Our patients should not have to wait to receive a test that can assist in a more accurate diagnosis with appropriate management.